Comparison of S-100 versus hematoxylin and eosin staining for evaluating dermal invasion and peripheral margins by desmoplastic malignant melanoma

American Journal of Dermatopathology

Volumn 22, Issue 1, 2000, Pages 26-29

  Eng, William ^a   Tschen, Jaime A ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b St Joseph Dermatopathology   (United States)

Author keywords

Dermal; Desmoplastic malignant melanoma; Immunostain; Peripheral margin; S 100

Indexed keywords

ARTICLE; CANCER CLASSIFICATION; CANCER INVASION; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; MALE; MELANOMA; PRIORITY JOURNAL; SPINDLE CELL;

ADULT; AGED; AGED, 80 AND OVER; COLORING AGENTS; EOSINE YELLOWISH-(YS); FEMALE; HEMATOXYLIN; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; RETROSPECTIVE STUDIES; S100 PROTEINS; SKIN NEOPLASMS; STAINING AND LABELING; TUMOR MARKERS, BIOLOGICAL;

EID: 0033964393     PISSN: 01931091     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000372-200002000-00005     Document Type: Article

References (18)

1. Conley J, Latterly R, Orr W. Desmoplastic malignant melanoma (a rare variant of spindle cell melanoma). Cancer 1971;28:914-36.
2. Reed JG, Leonard DD. Neurotropic melanoma: a variant of desmoplastic melanoma. Am J Surg Pathol 1979;3:301-11.
3. Skelton HG, Smith KJ, Laskin WB, McCarthy WF, Gagnier JM, Graham JH, Lupton GP. Desmoplastic malignant melanoma. J Am Acad Dermatol 1995;32:717-25.
4. Jain S, Allen PW. Desmoplastic malignant melanoma and its variants. Am J Surg Pathol 1989;13:358-73.
5. Anstey A, McKee P, Wilson Jones E. Desmoplastic malignant melanoma: a clinicopathological study of 25 cases. Br J Dermatol 1993;129:359-71.
6. Gown AM, Vogel AM, Hoak D, Gough F, McNutt MA. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol 1986;123:195-203.
7. Skelton H III, Smith KJ, Barrett TL. HMB-45 staining in benign and malignant melanocytic lesions: a reflection of cellular activation. J Am Dermatopathol 1991;13:543-50.
8. Anstey A. Cerio R, Ramnarain N, Orchard G, Smith N, Wilson Jones E. Desmoplastic malignant melanoma: an immunocytochemical study of 25 cases. Am J Dermatopathol 1994;16:14-22.
9. Longacre TA, Egbert BM, Rouse RV. Desmoplastic and spindle-cell malignant melanoma: an immunohistochemical study. Am J Surg Pathol 1996;20:1489-500.
10. Carlson JA, Dickersin GR, Sober AJ, Barnhill RL. Desmoplastic neurotropic melanoma: a clinicopathologic analysis of 28 cases. Cancer 1995;75:478-94.
11. Nakajima T, Watanabe S, Yuichi S, Kameya T, Shimosato Y, Ishihara K. Immunohistochemical demonstration of S100 protein in malignant melanoma and pigmented nevus, and its diagnostic application. Cancer 1982;50:912-8.
12. Gaynor R, Irie R, Morton D, Herschman HR. S100 protein is present in cultured human malignant melanomas. Nature 1980; 286:400-1.
13. Warner T, Lloyd RV, Hafez GR, Angevine JM. Immunocytochemistry of neurotropic melanoma. Cancer 1984;53:254-7.
14. Reiman HM, Goellner JR, Woods JE, Mixter RC. Desmoplastic melanoma of the head and neck. Cancer 1987;60:2269-74.
15. Elenitsas R, Van Belle P, Elder D. In: Laboratory methods, Lever's histopathology of the skin. 8th ed. Philadelphia: Lippincott-Raven, 1997:59.
16. Clark WH Jr, From L, Bernardino EA, Mihm MC Jr. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969;29:705-26.
17. Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970;172: 902-8.
18. Smithers BM, McLeod GR, Little JH. Desmoplastic, neural transforming, and neurotropic melanoma: a review of 45 cases. Aust N Z J Surg 1990;60:967-72.